Given the interest in the emerging and evolving coronavirus (COVID-19) pandemic and the questions regarding how this will impact patients with alopecia (including alopecia areata and other alopecias) who are treated with systemic immunomodulating medication, we have created a secure, online, de-identified Personal Health Identifier (PHI)-free reporting registry.
We encourage clinicians worldwide to report ALL cases of COVID-19 in their alopecia patients treated with systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).
Reporting a case to this Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-Alopecia registry should take approximately 5 minutes.
Please report only confirmed COVID-19 cases, and report after sufficient time has passed to observe the disease course through resolution of acute illness and/or death.
With the collaboration of the international alopecia community, we will rapidly be able to define the impact of COVID-19 on patients with alopecia who are treated with systemic immunomodulating medication and how factors such as age, comorbidities, and systemic immunomodulating treatments impact COVID outcomes.
We hope you will actively contribute to this voluntary reporting system. Through broadscale participation and collaboration, we will be able to answer these very pressing questions for our alopecia patients and their caregivers.
We will provide regular, open access summaries of all reported cases in SECURE-Alopecia, for the benefit of the international alopecia community. If you have any questions about the registry, please contact COVID.Alopecia@nisrsolutions.com.
Please enter the tokens generated by your token generator (Mobile Phone App).
Enter backup token to log in. These tokens have been generated for you to print and keep safe. Please enter one of these backup tokens to login to your account.
You need to create an account before you can log into the Secure-Alopecia Registry and enrol your patients.